WuXi Biologics plans to expand manufacturing capacity for drug substance and drug product.
The state-of-the-art drug substance facility laid with 30,000 square metres is expected to double from 12,000 litres to 24,000 litres. This will greatly increase the manufacturing capacity for drug substances, supporting both clinical and commercial production.
The expansion of the sterile filling and freeze-drying plant is aimed at increasing its annual capacity to approximately ten million doses. The addition of a second variable filling line will allow for more efficient and flexible production processes.
This expansion is a significant step in enhancing the plant's capabilities and meeting the growing demand for pharmaceutical products.
The investment in these facilities not only adds new capacity but also enhances the existing manufacturing services by strengthening the team's ability to provide timely support in advancing their biologics towards commercialisation.
Name WuXi Biologics